Clinical Trial Update: QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating QL1706 in combination with chemotherapy and anlotinib for recurrent ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• QL1706

Snippet

Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Conditions: Treatment of Recurrent Ovarian Cancer | Phase 2 | Status: RECRUITING